in subgroup analyses, pooled results from studies with adjustment of potential confounders showed an 11% reduction for low doses (rr, 0.89; 95% ci, 0.80-0.99, p = 0.032; i(2) = 30.9%, p = 0.227) and 16% for high doses (rr, 0.84; 95% ci, 0.75-0.94, p = 0.002; i(2) = 24.1%, p = 0.267) of caffeine consumption in af risk.